Drugs
FDA approves treatment for rare blood disease
- Drug is administered every 8 weeks, easing patient burden
-
FDA approves new treatment for adult patients with rare, life-threatening blood disease FDA approves treatment for blood and bone marrow disorder
- For patients unable to tolerate current intensive chemotherapy
-
FDA approves first treatment for rare blood disease Fluoroquinolones linked to ruptures and tears in the aorta
- Reserve these antibiotics as the last option for at-risk patients
-
FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients FDA issues framework for Real-World Evidence Program
- Evaluating the potential use of RWE for making regulatory decisions
-
Real World Evidence
Navigate the Drugs Section
Bioterrorism, drug preparedness and natural disaster response
Drug Approvals and DatabasesCDER highlights key Web sites. Web page provides quick links to everything from acronyms to wholesale distributor and third-party logistics providers reporting.
Drug Safety and AvailabilityMedication Guides, Drug Shortages, Drug Safety Communications and Other Safety Announcements
Development & Approval Process (Drugs)Get to know FDA’s drug development and approval process -- ensuring that drugs work and that the benefits outweigh their known risks.
Looking for FDA Guidance, Compliance, & Regulatory Information? Web page provides quick links to a variety of topics.
News & EventsWhat's New on This Site, Drug Approval Listing, Meetings and Conferences
Science & Research (Drugs)Science & Research (Drugs). Learn about the process that drives CDER science and research.
Resources for YouFor Consumers, Health Professionals, Industry
News and Announcements
Drug Safety
Program Areas
- Advisory Committees (Drugs)
- Generic Drugs
Guidances (Drugs) Pharmaceutical Quality Resources Division of Nonprescription Drugs (DNDP) Pediatric and Maternal Health Product Development CDER Small Business & Industry Assistance (SBIA) - User Fees (BsUFA, GDUFA, PDUFA)
Warning Letters and Notice of Violation Letters to Pharmaceutical Companies
Spotlight
Recalls & Alerts
Approvals & Clearances
Stay Informed
Contact FDA
Division of Drug Information (CDER)
Office of Communications
10001 New Hampshire Avenue
Hillandale Building, 4th Floor
Silver Spring, MD 20993